Skip to main content
Premium Trial:

Request an Annual Quote

Marian Moser Jones, Steve Nadis, Sara Harris

Premium

Marian Moser Jones (“It’s Not About Plastics Anymore,” p. 22) is the managing editor of BioArray News, the global weekly newsletter on biochips and microarrays, a sister publication of Genome Technology. She zeroed in on the microarray world while covering genomics as a reporter at GenomeWeb, but otherwise has broad interests. When not reporting, Jones is studying public health at Columbia University. Jones hopes eventually to merge her interests in the molecular minutiae of genomics and the health care macrocosm by formulating 21st century health and science policy.

When Steve Nadis (“Building Trust with Technology,” p. 32), shown here with his daughter Juliet, arrived at First Genetic Trust’s R&D branch in New Jersey, director Andrea Califano greeted him warmly as “Our savior!” Nadis thought the company must really be in trouble until he realized Califano had mistaken him for a guy who’d provided some last-minute programming wizardry. Califano toned down the reception when he realized that Nadis was just another writer from Cambridge, Mass., with some book credits and unsold movie scripts to his name.

According to Sara Harris, (“The Great Integrator,” p. 48) Hiroaki Kitano’s Systems Biology Institute differs from Lee Hood’s similarly named institute on more than just approach: “Bordered on one side by the Kirin brewery offices and on the other by the latest rock and hip-hop fashions, with a Condomania shop right on the main street, Harajuku has sex, drugs (beer, anyway), and rock ’n’ roll written all over it.” Harris, a Tokyo-based freelancer says, “Somehow the trendy address fits well the forward-looking office and its young staff. Where else could you spend your lunch hour watching soccer and developing a robot who can give you the play-by-play?”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.